Huimin Kong

Huimin Kong

Auto-generated profile, based on publicly available information

Huimin Kong

Laboratory of Biomaterials and Translational Medicine, Center for Nanomedicine, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2023 in Science Advances
Verified
Journal Article
Open access
CZChunxiong Zheng
Chunxiong Zheng
QZQingguo Zhong
Qingguo Zhong
KYKe Yi
Ke Yi
HKHuimin Kong
Huimin Kong
FCFangfang Cao
Fangfang Cao
Mingqiang LiMingqiang Li
Mingqiang Li
Equipping multiple functionalities on adoptive effector cells is essential to overcome the complex immunological barriers in solid tumors for superior antitumor efficacy. However, current cell engineering technologies cannot endow these functionalities to cells within a single step because of the different spatial distributions of targets in one cell. Here, we present a core-shell anti-phagocytosis-blocking repolarization-resistant membrane-fusogenic liposome (ARMFUL) to achieve one-step multiplexing cell engineering for multifunctional cell construction. Through fusing with the M1 macrophage membrane, ARMFUL inserts an anti-CD47 (aCD47)–modified lipid shell onto the surface and simultaneously delivers colony-stimulating factor 1 receptor inhibitor BLZ945-loaded core into the cytoplasm. The surface-presenting aCD47 boosts macrophage's phagocytosis against the tumor by blocking CD47. The cytoplasm-located BLZ945 prompts its polarization resistance to M2 phenotype in the immunosuppressive microenvironment via inactivating the intracellular M2 polarization signaling pathway. This ARMFUL provides a versatile cell engineering platform to customize multimodal cellular functions for enhanced adoptive cell therapy.

3 March 2025 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
HKHuimin Kong
Huimin Kong
XCXiaodie Chen
Xiaodie Chen
WLWeijen Lee
Weijen Lee
XXXi Xie
Xi Xie
Yu TaoYu Tao
Yu Tao
Mingqiang LiMingqiang Li
Mingqiang Li

9 May 2025 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
HKHuimin Kong
Huimin Kong
KYKe Yi
Ke Yi
XZXiang Zhu
Xiang Zhu
LCLifa Chen
Lifa Chen
HWHaixia Wang
Haixia Wang
Mingqiang LiMingqiang Li
Mingqiang Li

5 November 2021 in Blood
Verified
Journal Article
Open access
Mo YangMo Yang
Mo Yang
WSWeiqing Su
Weiqing Su
LYLiuming Yang
Liuming Yang
HKHuimin Kong
Huimin Kong
HWHuiling Wei
Huiling Wei
LLLiang Li
Liang Li
Background: Angelica Polysaccharide (APS) is from the root of Radix Angelicae Sinensis (Danggui). Danggui has been used for centuries to treat blood-deficiency related diseases. The hematopoietic effect of Danggui may be related to its constituent, polysaccharide. The effects of angelica polysaccharide on cryopreservation of platelets and megakaryocytes have not been well studied. This study focused on anti-apoptotic effect of APS and TPO on cryopreservation of platelets and megakaryocytes and provided new methods for prolonging the preservation time of platelets in vitro. Methods: The expression of platelet membrane glycoprotein CD41 and CD61, as well as the platelet apoptotic rate, Caspase 3 expression and mitochondrial membrane potential (MMP) were detected by flow cytometry; the anti-apoptotic mechanism of APS by PI3K /AKT signaling pathway was analyzed by Western blot assay. CFU assays were used to determine the effects of APS on megakaryocytic progenitor cells. Analyses of Annexin V, Caspase-3, and Mitochondrial Membrane Potential were conducted in megakaryocytic cell line M-07e. The effects of APS on cells treated with Ly294002, PI3K inhibitor and the effect of APS on the p-AKT were also studied. Results: The platelets were divided into 4 group: control group (4 ℃ stored platelets), APS group (APS-treated platelets stored at 4 ℃), LY294002 group (LY294002-treated platelets stored at 4 ℃) and LY294002+APS group (LY294002+APS treated platelets stored at 4 ℃). The apoptotic rate of platelets in LY294002 group was obviously increased. Compared with control group, the expression of CD41 and CD61 gradually decreased along with the enhancement of LY294002 concentrations (r=-0.953). The apoptotic rate of platelets in LY294002 group was enhanced significantly (P<0.05). While in LY294002+APS group, the apoptotic rate of platelets was significantly reduced (P<0.05) as compare with LY294002 group, which suggest that APS has an anti-apoptotic effect on the cryopreserved platelets. APS decreased the expression of Caspase-3 and inhibited the reduction of mitochondrial membrane potential induced by LY294002. Moreover, APS increased the activation of PI3K /AKT pathway in Platelets . We further analyzed the in vitro effect of APS on CFU-MK formation. APS (50 ug/ml) enhanced TPO (50 ng/ml) -induced CFU-MK formation (p=0.06, n=4). APS also significantly enhanced PDGF, bFGF and VEGF-induced CFU-MK formation (n=4). Moreover, the anti-apoptotic effect of APS in M-07e cells was also demonstrated by Annexin-V, Caspase-3, and JC-1 assays. Adding LY294002 alone increased the percentage of cells undergoing apoptosis. However, additional of APS to LY294002-treated cells reversed the percentage of cells undergoing apoptosis. Furthermore, addition of APS significantly increased the p-AKT. Conclusion: APS, like TPO, has an anti-apoptotic effect on the cryopreserved platelets and megakaryocytes through activating PI3K/AKT, decreasing the expression of Caspase-3 and inhibiting the reduction of MMP.

21 June 2021 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
PDF file
HKHuimin Kong
Huimin Kong
SLShixian Lv
Shixian Lv
Mingqiang LiMingqiang Li
Mingqiang Li
Jianxun DingJianxun Ding
Jianxun Ding
Editorial: Synthesis, Functionalization, and Clinical Translation of Pharmaceutical Biomaterials